Holen Sie sich die Stockscreener-App
71.98
1.61%
1.14
Vorhandelsmarkt:
71.14
-0.84
-1.17%
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Stifel upgrades Arcellx stock, cites buying opportunity after share weakness By Investing.com - Investing.com South Africa
Stifel upgrades Arcellx stock, cites buying opportunity after share weakness - Investing.com
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM - Clinical Trials Arena
Arcellx Inc. (ACLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Arcellx Inc. Stock Surge: Time to Buy? - StocksToTrade
Arcellx Reports Promising Phase 2 Study Results - TipRanks
Arcellx, Inc. Announces Positive Data from iMMagine-1 Study - TradingView
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $130 - 富途牛牛
Analyst Maintains 'Buy' Rating on Arcellx (ACLX) with Target Pri - GuruFocus
Arcellx (NASDAQ:ACLX) Given Buy Rating at Canaccord Genuity Group - MarketBeat
Why Is Arcellx Stock Surging Today? - Benzinga
Arcellx (NASDAQ:ACLX) Shares Gap UpShould You Buy? - MarketBeat
Arcellx shares jump on strong multiple myeloma trial results - MSN
Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Arcellx Inc - TipRanks
Arcellx stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com UK
Arcellx (NASDAQ:ACLX) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating for ACLX with $105 Price Target | - GuruFocus
Arcellx stock soars after positive multiple myeloma therapy data - Investing.com
Arcellx surges after promising data from mid-stage cancer therapy trial - TradingView
Arcellx Says Phase 2 Cancer Study Shows 96% Overall Response Rate; Shares Up Pre-Bell - marketscreener.com
Arcellx Inc’s Anito-cel: Promising CAR-T Therapy with Superior Safety Profile and Market Readiness - TipRanks
Arcellx Inc’s Promising Future: Buy Rating Backed by Strong Efficacy, Safety, and Strategic Partnerships - TipRanks
Why Have Arcellx Inc Stocks Plummeted? - TipRanks
Arcellx Inc (NASDAQ:ACLX) Nasdaq Index Biotech Momentum - Kalkine Media
Assessing Arcellx (ACLX) Valuation Following Positive Pivotal CAR T Data and Commercial Launch Plans - Yahoo Finance
Optimistic Buy Rating for Arcellx Inc: Promising Anito-cel Therapy and Strategic Advancements - TipRanks
Arcellx Inc’s Promising iMMagine-1 Study and Strategic Plans Justify Buy Rating and $112 Price Target - TipRanks
Arcellx announces new data for its iMMagine-1 study in patients with RRMM - TipRanks
Trading the Move, Not the Narrative: (ACLX) Edition - news.stocktradersdaily.com
Arcellx (NASDAQ: ACLX) iMMagine-1 shows 96% ORR, 74% CR/sCR in Phase 2 RRMM - Stock Titan
Schroder Investment Management Group Acquires New Position in Arcellx, Inc. $ACLX - MarketBeat
Affinity Asset Advisors LLC Sells 35,000 Shares of Arcellx, Inc. $ACLX - MarketBeat
Arcellx (NASDAQ:ACLX) Stock Price Down 6.2%Here's Why - MarketBeat
Will Arcellx Inc. stock deliver shareholder valuePortfolio Value Report & Daily Stock Momentum Reports - Newser
Russell Investments Group Ltd. Decreases Holdings in Arcellx, Inc. $ACLX - MarketBeat
Decheng Capital LLC Has $36.06 Million Stake in Arcellx, Inc. $ACLX - MarketBeat
Arcellx Earnings Notes - Trefis
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting - MSN
Arcellx (ACLX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Setup Watch: Can Arcellx Inc stock continue upward trendJuly 2025 Intraday Action & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
16,787 Shares in Arcellx, Inc. $ACLX Bought by XTX Topco Ltd - MarketBeat
Arcellx, Inc. $ACLX Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Arcellx, Inc. $ACLX Shares Acquired by American Century Companies Inc. - MarketBeat
FY2025 EPS Estimates for Arcellx Cut by Cantor Fitzgerald - MarketBeat
SG Americas Securities LLC Purchases Shares of 5,315 Arcellx, Inc. $ACLX - MarketBeat
Jefferies Financial Group Inc. Makes New Investment in Arcellx, Inc. $ACLX - MarketBeat
Citi says Arcellx weakness on ‘highly preliminary’ Kelonia data an overreaction - MSN
Arcellx, Inc. $ACLX Shares Acquired by Rhenman & Partners Asset Management AB - MarketBeat
Is Arcellx Inc. stock a defensive play in 2025Weekly Investment Summary & Weekly Stock Breakout Alerts - BỘ NỘI VỤ
(ACLX) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Arcellx Inc’s Anito-cel: A Promising CAR-T Therapy with Strong Market Positioning and Growth Potential - TipRanks
Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail
Assessing Arcellx (ACLX) Valuation Following New CAR-T Therapy Competition from Kelonia Therapeutics - Sahm
Arcellx stock maintains Buy rating at Stifel ahead of ASH 2025 data - Investing.com Australia
Arcellx stock maintains Buy rating at Stifel ahead of ASH 2025 data By Investing.com - Investing.com South Africa
Promising Outlook for Arcellx Inc’s Anito-cel Therapy in Multiple Myeloma Treatment - TipRanks
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma - MSN
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):